#MRK #CDTX Merck to Complete Acquisition of Cidara Therapeutics
www.stocktitan.net/news/MRK/merck-to-comple...
0
0
0
0
#CDTX
Latest posts tagged with #CDTX on Bluesky
Trending
Posts tagged #CDTX
1
0
0
0
Just In: ( NASDAQ: #CDTX ) Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
0
0
0
0
NEWS: ( NASDAQ: #CDTX ) Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?
0
0
0
0
Breaking News: ( NASDAQ: #CDTX ) Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
0
0
0
0
🚀 Exciting times for #CDTX! After a 105% surge from Merck's $9.2B acquisition, it's trading at $219.35. Despite overbought RSI, the bullish MACD hints at more gains. Consider a short-term long if it stays above $215. Target: $225/$230, Stop: $210. 📈 #BiotechBoom
0
0
0
0
#CDTX Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
www.stocktitan.net/news/CDTX/cidara-therape...
0
0
0
0
🚨 Hot take on #CDTX! Despite a recent surge from Merck's $9.2B acquisition, Cidara faces legal challenges and Pfizer competition. RSI over 88 signals overbought—watch for a pullback! 📉 Consider shorting at $218, targeting $210/$200. Stay alert for news-driven moves! 📊 #Stocks #FeetrAI
0
0
0
0
🚀 #CDTX skyrockets 105% after Merck's big move! But watch out: legal scrutiny & an RSI over 88 hint at a pullback. MACD shows bullish vibes, yet broader market trends suggest caution. Short at $218? Target $200/$180, stop loss $230. FeetrAI's got the insights! 📈 #Stocks #Trading
0
0
0
0
🚀 Exciting times for #CDTX! After a 105% surge, it's trading at $218, riding high on Merck's acquisition and innovation buzz. Despite overbought RSI, MACD signals more gains. Consider going long at $215, aiming for $230-$240. Stay sharp with a $205 stop loss! 📈 #FeetrAI
0
0
0
0
🚨 Big moves for #CDTX! After a 105% surge from Merck's $9.2B acquisition, legal probes are stirring volatility. With RSI at 88.69, a pullback looms. Consider SHORT at $218, targeting $200 & $180. Stay alert for news—this one's a rollercoaster! 🎢 #FeetrAI #StockMarket
0
0
0
0
🚀 Big moves for #CDTX! A 105% surge after Merck's $9.2B acquisition news has traders buzzing. But with RSI over 88, a pullback might be on the horizon. Consider going LONG if it stabilizes at $219, targeting $225 & $230. Stay sharp—M&A news could shake things up! 📈 #FeetrAI
0
0
0
0
🚀 Exciting times for #CDTX! After a 105% surge post-Merck acquisition, this mRNA innovator is on fire! 🔥 Despite a bearish market, CDTX's momentum is strong. Consider a LONG position at $218.50, targeting $225 & $230. Stay alert for rapid shifts! #Biotech #Stocks #FeetrAI
0
0
0
0
🚀 Exciting times for #CDTX! With Merck's potential acquisition at $221.50/share, volatility is high. RSI over 88 signals caution, but bullish momentum is strong. Consider going LONG if it dips to $218, targeting $221.50 & $225. Stay sharp, traders! #StockMarket #FeetrAI
0
0
0
0
JUST IN: ( NASDAQ: #CDTX ) Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
0
0
0
0
BREAKING NEWS: ( NASDAQ: #CDTX ) Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
0
0
0
0
🚀 Exciting times for #CDTX! With Merck's acquisition offer at $221.50, the stock is surging! 📈 But watch out—RSI is over 88, signaling overbought conditions. Consider shorting if it can't break $221.50. Entry: $220, Targets: $215/$210, Stop: $222. Stay alert for news! #Stocks #TradingTips
0
0
0
0
0
0
0
0
#CDTX #MRK #BMRN #NKTR #e9b5d92d-cc59-43a7-b71e-fe0e2c65eae0 #investing #Health #Care
Origin | Interest | Match
0
0
0
0
🚀 Exciting times for #CDTX! With Merck's buyout at $221.50/share, current price of $219.22 offers a unique play. High RSI hints at pullbacks, but bullish MACD suggests potential gains. Consider going LONG at $219, targeting $221.50 & $225. Stay alert for acquisition updates! 📈 #FeetrAI
0
0
0
0
Breaking News: ( NASDAQ: #CDTX ) Cidara Therapeutics Inc. (NASDAQ: CDTX) Records 52-Week High Wednesday Morning
0
0
0
0
🚀 Exciting times for #CDTX! With Merck's acquisition news, the stock has surged 105%! 📈 RSI is overbought, but MACD shows bullish momentum. Watch for a breakout above $219.50 with targets at $221.50 & $225. Set stop loss at $215. Stay alert for any market twists! #FeetrAI
0
0
0
0
🚀 Exciting times for #CDTX! With Merck's acquisition offer at $221.50, the stock's trading just below at $218.50. RSI suggests overbought, but MACD shows bullish momentum. Consider a long position with targets at $221.50 & $225. Stay alert for merger news! 📈 #FeetrAI
0
0
0
0
🚀 Exciting times for #CDTX! With Merck's acquisition offer at $221.50, the stock is surging on innovation buzz and partnerships. But watch out—RSI is overbought at 88! Consider shorting if it hits $220, targeting $215 & $210. Stop loss at $223. Stay sharp! #FeetrAI 📈
0
0
0
0
🚀 Exciting times for #CDTX! With Merck eyeing an acquisition at $221.50/share, volatility is high. RSI over 88 signals caution, but bullish momentum is strong. Consider entry at $215, targeting $220 & $225. Stay alert for acquisition updates! 📈 #StockWatch #FeetrAI
0
0
0
0
🚀 Exciting times for #CDTX! With Merck's acquisition at $221.50/share, CDTX is buzzing with volatility, trading around $218.01. RSI signals overbought, but MACD shows bullish vibes. Consider a long position with targets at $220 & $221.50. Watch for news! 📈 #FeetrAI
0
0
0
0
🚀 Exciting times for #CDTX! With Merck's acquisition offer at $221.50, the stock is surging! 📈 RSI over 88 signals a potential pullback, but bullish momentum is strong. Consider going LONG at $218, targeting $220 & $221.50. Stay alert for acquisition news! #Stocks #TradingTips
0
0
0
0
🚀 Exciting times for #CDTX! With Merck's acquisition at $221.50/share, CDTX is buzzing with volatility. Overbought RSI of 88.7 hints at a pullback, but bullish MACD keeps the momentum alive. Consider going LONG at $217.50, targeting $220 & $221.50. Stay sharp! 📈 #FeetrAI
0
0
0
0